Identification of metallopanstimulin-1 as a member of a tumor associated antigen in patients with breast cancer

The immunological screening of breast cancer was performed with IgG autoantibodies by the serological analysis of recombinant cDNA expression library methods to explore novel tumor associated antigens. We have focused on a small zinc finger protein metallopanstimulin-1 (MPS-1). MPS-1 mRNA was ubiqui...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2002-08, Vol.182 (1), p.101-107
Main Authors: Atsuta, Yoshiaki, Aoki, Naoko, Sato, Keisuke, Oikawa, Kensuke, Nochi, Hitoshi, Miyokawa, Naoyuki, Hirata, Satoshi, Kimura, Shoji, Sasajima, Tadahiro, Katagiri, Makoto
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - analysis
Biological and medical sciences
Breast cancer
Breast Neoplasms - immunology
Breast Neoplasms - therapy
Cloning
DNA, Complementary - analysis
Female
Gene Library
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
Immunoscreening
Immunotherapy
Mammary gland diseases
Medical sciences
Melanoma
Metalloproteins - analysis
Metalloproteins - genetics
Nuclear Proteins - analysis
Nuclear Proteins - genetics
Proteins
Ribosomal Proteins
RNA, Messenger - analysis
RNA-Binding Proteins
SEREX
Tumor Cells, Cultured
Tumors
Zinc finger protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The immunological screening of breast cancer was performed with IgG autoantibodies by the serological analysis of recombinant cDNA expression library methods to explore novel tumor associated antigens. We have focused on a small zinc finger protein metallopanstimulin-1 (MPS-1). MPS-1 mRNA was ubiquitously expressed in normal human tissues except the brain and the placenta. In Western blot analysis, MPS-1 was easily detected strongly in actively proliferating cells and three breast cancer cell lines. In the tissue the protein of MPS-1 in cancer cells was more abundant than that of surrounding normal cells. Screening of tissue specimens by immunohistochemistry revealed 50.4% positive for MPS-1 in 125 cancer patients. These data suggest that MPS-1 could be applicable to the immunotherapy of breast cancer.
ISSN:0304-3835
1872-7980
DOI:10.1016/S0304-3835(02)00068-X